Earlier separate trials had pointed in this direction. SURMOUNT-1 enrolled 2,539 adults without diabetes and found tirzepatide at the 15 mg dose produced average weight loss of 22.5%, with 57% of participants achieving at least 20% weight loss and 89-91% reaching the 5% threshold [2]. The STEP 1 trial, semaglutide's pivotal obesity study, enrolled 1,961 non-diabetic adults and found 14.9% average weight loss, with 86% achieving at least 5% [3]. In people with type 2 diabetes, SURPASS-2 directly compared both drugs and found tirzepatide superior to semaglutide 1 mg at all three doses tested, with weight differences ranging from 1.9 kg to 5.5 kg in favor of tirzepatide [5].

Real-world data reinforces what the trials show. A propensity-matched retrospective cohort of 18,386 patients published in JAMA Internal Medicine found tirzepatide users were 1.76 times more likely to achieve at least 5% weight loss, 2.54 times more likely to achieve at least 10%, and 3.24 times more likely to achieve at least 15% weight loss, with the gap widening to 6.9 percentage points at 12 months [9]. A 2025 meta-analysis confirmed a mean difference of 4.23 kg favoring tirzepatide (95% CI 3.22-5.25; p<0.01), rising to 6.50 kg in high-dose subgroups [10]. The advantage is consistent across trial types and most pronounced at maximum doses and longer durations.

Beyond Weight Loss: Cardiovascular and Metabolic Outcomes

Weight loss alone does not fully capture why these drugs matter for health. The more consequential question is whether they reduce the risk of heart attacks, strokes, and other serious cardiovascular events. Here the evidence base is asymmetric because the drugs have been in clinical development at different rates.

Semaglutide has the more mature cardiovascular dataset. The SELECT trial, a dedicated cardiovascular outcomes trial, enrolled 17,604 adults with obesity, established cardiovascular disease, and no diabetes, following them for nearly 40 months [7]. Semaglutide reduced major adverse cardiovascular events by 20% compared with placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001), with event rates of 6.5% versus 8.0% [7]. That is a landmark finding: a weight-loss drug reducing hard cardiovascular endpoints in a population defined by high cardiovascular risk, independent of diabetes status.

Tirzepatide's cardiovascular data are newer and structured differently. SURPASS-CVOT, published in the New England Journal of Medicine in 2025, enrolled 13,165 adults with type 2 diabetes and compared tirzepatide against dulaglutide rather than placebo [8]. Tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events (12.2% vs 13.1%, HR 0.93), and an expanded MACE definition further favored tirzepatide (HR 0.88) [8]. Demonstrating superiority to placebo in a non-diabetic cardiovascular outcomes trial, as SELECT did for semaglutide, awaits further study.

On broader metabolic outcomes, both drugs improve markers across the board: blood pressure, triglycerides, HDL cholesterol, liver fat, and markers of insulin resistance. In SURMOUNT-2, tirzepatide reduced body weight by 12.8% to 14.7% in adults with type 2 diabetes, with 48% to 55% achieving at least 15% weight loss [6]. These outcomes carry substantial downstream benefits for glucose control, kidney function, and fatty liver disease.

Side Effects, Tolerability, and Who Should Avoid Each

Both drugs produce a recognizable side effect pattern: gastrointestinal symptoms concentrated in the early dose-escalation period. Nausea, vomiting, diarrhea, and constipation are the most frequent complaints, following a predictable arc that is most intense during ramp-up and diminishes as the body adjusts to stable dosing. Both use slow, stepwise escalation schedules for this reason [2, 3].

Where the two drugs differ in tolerability is directly documented in SURMOUNT-5. Discontinuation due to gastrointestinal adverse events occurred in 2.7% of the tirzepatide group compared with 5.6% in the semaglutide group [1]. The STEP 1 trial reported nausea in 44.2% of semaglutide participants versus 17.4% on placebo, with a gastrointestinal discontinuation rate of 4.5% [3]. The meta-analysis by Bin Aamir et al. found similar overall GI safety profiles between the two drugs, with no statistically significant difference in total adverse event rates [10]. The direct comparison data gives tirzepatide a modest edge in tolerability at maximum doses.

Both drugs share key contraindications. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), based on animal study signals carrying the highest-level regulatory warning. Both are contraindicated in pregnancy and should be discontinued at least two months before attempting conception. Both carry caution in people with a history of pancreatitis, severe gastrointestinal disease, or significant kidney or liver impairment.

People whose primary goal is cardiovascular risk reduction in established CVD without diabetes have more direct evidence supporting semaglutide, given SELECT's findings. People with type 2 diabetes being managed for both weight and glucose control will find both drugs studied extensively in that population.

Practical Guide: Dosing, Access, and How to Choose

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for obesity) is dosed once weekly, starting at 2.5 mg and escalating in 2.5 mg steps every four weeks through 5, 7.5, 10, 12.5, and up to 15 mg at maximum. Semaglutide (Ozempic for diabetes, Wegovy for obesity) is also dosed once weekly, starting at 0.25 mg for four weeks, then escalating through 0.5, 1, 1.7, and up to 2.4 mg for obesity. Both require subcutaneous self-injection, typically in the abdomen, thigh, or upper arm.

Access and cost vary by country and insurance status. In the United States, both drugs carry list prices exceeding $1,000 per month without coverage, though manufacturer savings programs and pharmacy discount programs can substantially reduce out-of-pocket costs. Wegovy has broader insurance coverage in some markets due to its longer tenure. Zepbound gained FDA approval for obesity in late 2023 and coverage is expanding. People outside the United States will find varying approval statuses and pricing structures.

How to choose is a conversation best had with a healthcare provider who knows your medical history. A few patterns emerge from the evidence. If maximizing weight loss is the primary goal and both drugs are accessible, the data consistently favor tirzepatide, particularly at maximum doses. If you have established cardiovascular disease without diabetes, your provider may weigh semaglutide's SELECT data heavily. If you have type 2 diabetes and need meaningful glucose control alongside weight loss, both drugs are extensively studied in that population, with tirzepatide showing stronger effects across comparison trials. Cost, insurance formulary, and your provider's prescribing experience may ultimately be the deciding factors, and that is a legitimate, pragmatic basis when both options carry strong evidence.

Frequently Asked Questions

Is tirzepatide significantly better than semaglutide for weight loss?

The head-to-head evidence says yes. SURMOUNT-5, the only randomized controlled trial comparing both drugs directly in people with obesity, found tirzepatide produced 20.2% average body weight reduction versus 13.7% for semaglutide over 72 weeks, a 6.5 percentage point difference [1]. Real-world data from 18,386 propensity-matched patients found tirzepatide users were 3.24 times more likely to achieve at least 15% weight loss at 12 months [9]. The advantage is consistent across trial types and is most pronounced at maximum doses.

Does semaglutide have better heart health data than tirzepatide?

For now, yes, with an important qualification. Semaglutide's SELECT trial demonstrated a 20% reduction in major cardiovascular events versus placebo in adults with obesity, established CVD, and no diabetes [7]. Tirzepatide's SURPASS-CVOT trial showed noninferiority to dulaglutide in people with type 2 diabetes but was not a placebo-controlled cardiovascular superiority trial in a non-diabetic obese population [8]. The comparison is not apples-to-apples, and tirzepatide cardiovascular outcomes studies in non-diabetic populations are ongoing.

Which drug has fewer side effects?

Both drugs cause gastrointestinal side effects, primarily nausea, vomiting, diarrhea, and constipation, concentrated during dose escalation. In the SURMOUNT-5 head-to-head trial, the gastrointestinal discontinuation rate was lower for tirzepatide (2.7%) than semaglutide (5.6%) [1]. A meta-analysis found similar overall GI safety profiles between the two drugs [10]. The direct comparison data gives tirzepatide a modest edge in tolerability at maximum doses.

Can I switch from semaglutide to tirzepatide?

Switching is possible and does occur in clinical practice, but it should be done under the guidance of a prescribing provider who can assess the appropriate starting dose, whether a washout period is needed, and how to manage the transition safely given your current clinical status. Clinical guidance suggests starting tirzepatide at a low dose and escalating as with any new patient.

How long do you need to stay on these drugs?

Current evidence indicates weight returns after stopping either drug, as both work by maintaining an active hormonal signal that the body does not sustain on its own after discontinuation. Long-term data at two years from STEP 5 found semaglutide maintained 15.2% weight loss [4]. Most clinical frameworks now treat these as long-term or indefinite therapies for people with obesity, similar to medications for blood pressure or cholesterol. The decision to continue, pause, or stop should be made with a provider based on your individual risk-benefit assessment.

References

[1] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2416394

[2] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038

[3] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183

[4] Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022. DOI: 10.1038/s41591-022-02026-4

[5] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2107519

[6] Garvey WT, et al. Tirzepatide for obesity with type 2 diabetes (SURMOUNT-2). The Lancet. 2023. DOI: 10.1016/S0140-6736(23)01200-X

[7] Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2307563

[8] Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2505928

[9] Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine. 2024. DOI: 10.1001/jamainternmed.2024.2525

[10] Bin Aamir A, et al. Comparative Efficacy of Tirzepatide vs. Semaglutide: Systematic Review and Meta-Analysis. Journal of Clinical Medicine Research. 2025. DOI: 10.14740/jocmr6231

This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.